Elevated lactoferrin is associated with moderate to severe Clostridium difficile disease, stool toxin, and 027 infection

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 32, Issue 12, 2013, Pages 1517-1523

  Boone, J H ^a   Dipersio, J R ^b   Tan, M J ^b   Salstrom, S J ^b   Wickham, K N ^a   Carman, R J ^a   Totty, H R ^a   Albert, R E ^a   Lyerly, D M ^a  

^a TECHLAB INC   (United States)

^b SUMMA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BACTERIAL TOXIN; BIOLOGICAL MARKER; GLUTAMATE DEHYDROGENASE; LACTOFERRIN;

ABDOMINAL PAIN; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BACTERIUM CULTURE; BLOOD; BLOOD ANALYSIS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; CYTOTOXICITY; DISEASE SEVERITY; ENTERITIS; FECES; FECES ANALYSIS; FEMALE; HUMAN; INFECTION RATE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TISSUE CULTURE; TOXIN ANALYSIS;

AGED; ANALYSIS OF VARIANCE; BACTERIAL TOXINS; BIOLOGICAL MARKERS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FECES; FEMALE; HUMANS; LACTOFERRIN; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RIBOTYPING; SERUM ALBUMIN;

EID: 84887988539     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-013-1905-x     Document Type: Article

References (40)

1. Archbald-Pannone L, Sevilleja JE, Guerrant R (2010) Diarrhea, Clostridium difficile, and intestinal inflammation in residents of a long-term care facility. J Am Med Dir Assoc 11(4):263-267
2. Bartlett JG, Perl TM (2005) The new Clostridium difficile - what does it mean? N Engl J Med 353:2503-2505
3. Barbut F, Rupnik M (2012) Editorial commentary: 027, 078, and others: going beyond the numbers (and away from the hypervirulence). Clin Infect Dis 55(12):1669-1672
4. Boone JH, Goodykoontz M, Rhodes SJ, Price K, Smith J, Gearhart KN et al (2012) Clostridium difficile prevalence rates in a large healthcare system stratified according to patient population, age, gender, and specimen consistency. Eur J Clin Microbiol Infect Dis 31(7):1551-1559
5. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC et al (2010) Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 31(5):431-455
6. Drudy D, Kyne L, O'Mahony R, Fanning S (2007) gyrA mutations in fluoroquinolone-resistant Clostridium difficile PCR-027. Emerg Infect Dis 13:504-505
7. Eyre DW, Walker AS, Wyllie D, Dingle KE, Griffiths D, Finney J, et al (2012) Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis 55:S77-S87
8. Ghantoji SS, Sail K, Lairson DR, Dupont HL, Garey KW (2010) Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect 74:309-318
9. Guerrant RL, Araujo V, Soares E, Kotloff K, Lima AA, Cooper WH et al (1992) Measurement of fecal lactoferrin as a marker of fecal leukocytes. J Clin Microbiol 30:1238-1242
10. Hubert B, Loo VG, Bourgault AM, Poirier L, Dascal A, Fortin E et al (2007) A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Québec. Clin Infect Dis 44:238-244
11. Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D et al (2003) Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 98(6):1309-1314
12. Kazakova SV, Ware K, Baughman B, Bilukha O, Paradis A, Sears S et al (2006) A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. Arch Intern Med 166:2518-2524
13. Kelly CP, Loo VG (eds) (2008) Current concepts in Clostridium difficile infection: a focus on severe disease. CME Newsl vol 2, issue 2, pp 1-6
14. 2 up-regulation of Fas ligand. Gastroenterology 133:875-886
15. Koo HL, Ajami NJ, Jiang ZD, Dupont HL, Atmar RL, Lewis D et al (2009) A nosocomial outbreak of norovirus infection masquerading as Clostridium difficile infection. Clin Infect Dis 48:e75-e77
16. Langhorst J, Boone J (2012) Fecal lactoferrin as a noninvasive biomarker in inflammatory bowel diseases. Drugs Today (Barc) 48(2):149-161
17. LaSala PR, Ekhmimi T, Hill AK, Farooqi I, Perrotta PL (2013) Quantitative fecal lactoferrin in toxin-positive and toxin-negative Clostridium difficile specimens. J Clin Microbiol 51(1):311-313
18. Leffler DA, Lamont JT (2009) Treatment of Clostridium difficile-associated disease. Gastroenterology 136:1899-1912
19. Lewis SJ, Heaton KW (1997) Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 32(9):920-924
20. Linevsky JK, Pothoulakis C, Keates S, Warny M, Keates AC, Lamont JT et al (1997) IL-8 release and neutrophil activation by Clostridium difficile toxin-exposed human monocytes. Am J Physiol 273:G1333-G1340
21. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S et al (2005) A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 352:2442-2449
22. McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP et al (2005) An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353:2433-2441
23. Morgan OW, Rodrigues B, Elston T, Verlander NQ, Brown DF, Brazier J et al (2008) Clinical severity of Clostridium difficile PCR ribotype 027: a case-case study. PLoS One 3:e1812
24. O'Brien JA, Lahue BJ, Caro JJ, Davidson DM (2007) The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 28:1219-1227
25. Pawlowski SW, Archbald-Pannone L, Carman RJ, Alcantara-Warren C, Lyerly D, Genheimer CW et al (2009) Elevated levels of intestinal inflammation in Clostridium difficile infection associated with fluoroquinolone-resistant C. difficile. J Hosp Infect 73(2):185-187
26. Pépin J, Valiquette L, Cossette B (2005) Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 173(9):1037-1042. doi: 10.1503/cmaj.050978
27. Planche TD, Davies KA, Coen PG, Crook D, Shetty N, Wren M et al (2012) Clinical validation of Clostridium difficile infection (CDI) diagnostics: importance of toxin detection. In: Proceedings of the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, September 2012
28. Pothoulakis C, Sullivan R, Melnick DA, Triadafilopoulos G, Gadenne AS, Meshulam T et al (1988) Clostridium difficile toxin A stimulates intracellular calcium release and chemotactic response in human granulocytes. J Clin Invest 81:1741-1745
29. Savidge TC, Pan WH, Newman P, O'Brien M, Anton PM, Pothoulakis C (2003) Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine. Gastroenterology 125:413-420
30. Schoepfer AM, Trummler M, Seeholzer P, Seibold-Schmid B, Seibold F (2008) Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 14:32-39
31. Sipponen T, Savilahti E, Kärkkäinen P, Kolho KL, Nuutinen H, Turunen U et al (2008) Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis 14(10):1392-1398
32. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Färkkilä M (2007) Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 14:40-46
33. Stubbs SL, Brazier JS, O'Neill GL, Duerden BI (1999) PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 37:461-463
34. Sugi K, Saitoh O, Hirata I, Katsu K (1996) Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol 91(5):927-934
35. Surawicz CM, McFarland LV (1999) Pseudomembranous colitis: causes and cures. Digestion 60:91-100
36. Tan ET, Robertson CA, Brynildsen S, Bresnitz E, Tan C, McDonald C (2007) Clostridium difficile-associated disease in New Jersey hospitals, 2000-2004. Emerg Infect Dis 13:498-500
37. Walk ST, Micic D, Jain R, Lo ES, Trivedi I, Liu EW et al (2012) Clostridium difficile ribotype does not predict severe infection. Clin Infect Dis 55(12):1661-1668
38. Walker TR, Land ML, Kartashov A, Saslowsky TM, Lyerly DM, Boone JH et al (2007) Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 44:414-422
39. Wren MW, Kinson R, Sivapalan M, Shemko M, Shetty NR (2009) Detection of Clostridium difficile infection: a suggested laboratory diagnostic algorithm. Br J Biomed Sci 66(4):175-179
40. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB (2007) A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45:302-307